Content by Keyword: Substance Abuse and Mental Health

  • Home
  • Substance Abuse and Mental Hea...
  • print
  • email
  • twitter
  • compact
Report page
ACKNOWLEDGMENTS

Review of Medication-Assisted Treatment Guidelines and Measures for Opioid and Alcohol Use. Acknowledgments

Mathematica Policy Research prepared this review under contract to the Office of the Assistant Secretary for Planning and Evaluation (ASPE), U.S. Department of Health and Human Services (HHS) (HHSP23320100019WI/HHSP23337001T). Additional funding was provided by the HHS Substance Abuse and Mental Health Services Administration (SAMHSA). The authors
Report
Review of Medication-Assisted Treatment

Review of Medication-Assisted Treatment Guidelines and Measures for Opioid and Alcohol Use

Stefanie Pietras, Melissa Azur and Jonathan Brown Mathematica Policy Research ABSTRACT
  • MATguidelines.pdf
    export-csvPDF
PDF report
Review of Medication-Assisted Treatment

Review of Medication-Assisted Treatment Guidelines and Measures for Opioid and Alcohol Use

In response to the growing opioid epidemic, HHS announced a three-pronged initiative in March 2015 to: (1) improve opioid prescribing practices; (2) increase access to naloxone for overdose management; and (3) expand medication-assisted treatment (MAT) to reduce opioid dependence. In support of the initiative, ASPE contracted with Mathematica Poli
  • MATguidelines.pdf
    export-csvPDF
PDF report
Benefits of Medicaid Expansion for Behavioral

Benefits of Medicaid Expansion for Behavioral Health

Across the country, state and local officials are increasingly focused on improving health outcomes for people living with mental illness or substance use disorders. This brief analyzes national data on behavioral health and reviews published research focused on how Medicaid expansion under the Affordable Care Act advances the goal of improving tr
  • BHMedicaidExpansion.pdf
    export-csvPDF
Report page
Reference List

Access and Utilization of New Antidepressant and Antipsychotic Medications. Reference List

1. Health Care Financing Administration(now known as Centers for Medicare and Medicaid Services(CMS)). National health expenditures projections. 1999. 2. National health expenditures aggregate amounts and average annual percent change, by type of expenditure: selected calendar years 1960-97. Accessed November 17, 1999. Web Page. Availab
Report page
Appendix C. Interview Respondents

Access and Utilization of New Antidepressant and Antipsychotic Medications. Appendix C. Interview Respondents

Stakeholder Group Interviews Completed Request for Interview Refused or Unable to Schedule Federal Government Health Care Financing Administration(now known as Centers for Medicare and Medicaid Services(CMS)) Indian Health Service Navajo Region Department of Defense (DoD) Pharmaco-Economic Center Mental Hea
Report page
J. Consumer Advocay Associations

Access and Utilization of New Antidepressant and Antipsychotic Medications. J. Consumer Advocay Associations

Two consumer associations, the National Alliance for the Mentally Ill (NAMI) and the National Mental Health Association (NMHA), were selected because of their national presence in the mental health field. Additionally, NAMI specializes in advocating for consumers who suffer from schizophrenia and their families. These two organizations' perspectiv
Report page
I. Professional Associations

Access and Utilization of New Antidepressant and Antipsychotic Medications. I. Professional Associations

Two professional associations, the American Psychiatric Association (APA), which represents psychiatrists, and the American Academy of Family Physicians (AAFP), which represents family physicians, were identified to participate in this study.
Report page
H. Corrections System

Access and Utilization of New Antidepressant and Antipsychotic Medications. H. Corrections System

The corrections system was selected as an interview type because of the documented mental illness of the population it serves. More specifically, New York's correctional system was identified through expert recommendations as an appropriate interview target because it is well-known for instituting a progressive and innovative prison system statewi
Report page
G. State Mental Health Systems

Access and Utilization of New Antidepressant and Antipsychotic Medications. G. State Mental Health Systems

The following criteria were used to identify four public sector mental health systems to be interviewed:
Report page
F. Federal and State Programs (HCFA(now known as

Access and Utilization of New Antidepressant and Antipsychotic Medications. F. Federal and State Programs (HCFA(now known as CMS), IHS, CHAMPUS, VA, Medicaid)

The Health Care Financing Administration(now known as Centers for Medicare and Medicaid Services(CMS)) (HCFA(now known as CMS)) and the Indian Health Service (IHS) were automatically selected without the use of specific criteria in order to provide a necessary background behind federally-operated and state- or tribally-administered public insuranc
Report page
E. Employers

Access and Utilization of New Antidepressant and Antipsychotic Medications. E. Employers

In order to gain an industry-wide perspective on the approach to behavioral health and pharmacy benefits, The Lewin Group interviewed the William Mercer Corporation. As a result, the following criteria were identified as necessary characteristics of the employers selected for this study:
Report page
D. Pharmaceutical Benefits Managers

Access and Utilization of New Antidepressant and Antipsychotic Medications. D. Pharmaceutical Benefits Managers

The following criteria were used to select the pharmacy benefit managers (PBMs) interviewed: National or regional market presence; Independently operated or carved out from other entity; and Linked to other interview respondent type (i.e., employer, Medicaid program). As a result, five PBMs were identified and interviewed: Value Rx/Expre
Report page
C. Large Integrated HMOs

Access and Utilization of New Antidepressant and Antipsychotic Medications. C. Large Integrated HMOs

In order to examine a more typical arrangement, The Lewin Group decided to focus on integrated health maintenance organizations (HMOs) for this study. Consequently, The Lewin Group identified participants based on the following criteria:
Report page
B. Managed Behavioral Health Care Organizations

Access and Utilization of New Antidepressant and Antipsychotic Medications. B. Managed Behavioral Health Care Organizations

The criteria used to select three managed behavioral health care organizations (MBHCOs) for this study included:
Report page
A. Pharmaceutical Companies

Access and Utilization of New Antidepressant and Antipsychotic Medications. A. Pharmaceutical Companies

Pharmaceutical manufacturers were selected based on the following criteria: 1) medium to large size company; and 2) company has current products and products in development in the area of newer atypical antidepressants and/or antipsychotics. As a result, Janssen, AstraZeneca, Eli Lilly, and GlaxoWellcome (GW) were selected. (1)  GW and Eli Lilly
Report page
Appendix B. Interview Strategy

Access and Utilization of New Antidepressant and Antipsychotic Medications. Appendix B. Interview Strategy

This study focused on identifying and interviewing individuals from a variety of organizations or programs represented by the following perspectives:
Report page
Appendix A. Interview Protocol

Access and Utilization of New Antidepressant and Antipsychotic Medications. Appendix A. Interview Protocol

The following document displays a generic form of the interview protocol used in this study. Please note that this template was tailored specifically for the type of respondent being interviewed.
Report page
Appendixes

Access and Utilization of New Antidepressant and Antipsychotic Medications. Appendixes

Report page
E. The Changing Role of Managed Care

Access and Utilization of New Antidepressant and Antipsychotic Medications. E. The Changing Role of Managed Care

Resistance to managed care has centered on the restriction of patients' choice of plan and provider; on plans' denial of services or reimbursement; and on plans' continual reduction of provider reimbursement rates. Both Congress and most state legislatures continue to consider Patients' Bill of Rights legislation as a way to ensure some level of q

Pages

Form Approved OMB# 0990-0379 Exp. Date 9/30/2020